In addition, we explored the prognostic significance of co-expression of OX-40/PD-L1 and OX-40/ICOS in the immune infiltrate in a subgroup of NSCLC samples, based on prior evidence of the potential role of these two T-cell markers as predictive markers of response to checkpoint inhibitor therapy in solid tumors [31–35]. Here, ICOS is linked to non-small cell lung carcinoma.